Design and Expression of a Dimeric Form of the Human Immunodeficiency Virus Type 1 Antibody 2G12 with Increased Neutralization Potency by West, Anthony P., Jr. et al.
Design and Expression of a Dimeric Form of the Human 
Immunodeficiency Virus Type 1 Antibody 2G12 with 
Increased Neutralization Potency 
 
Anthony P. West, Jr.,1 Rachel P. Galimidi,1 Christopher P. Foglesong,1 
Priyanthi N. P. Gnanapragasam,1 Kathryn E. Huey-Tubman,1,2 Joshua S. 
Klein,1 Maria D. Suzuki,1 Noreen E. Tiangco,1 Jost Vielmetter, 1,3  
Pamela J. Bjorkman1,2* 
 
Division of Biology1, Howard Hughes Medical Institute2, 
 and the Caltech Protein Expression Center3 
California Institute of Technology 
1200 E. California Blvd. 
Pasadena, CA 91125 
 
*Corresponding author. Mailing address: Division of Biology, California Institute of 
Technology, 1200 E. California Blvd., Pasadena, CA 91125. Phone: 626-395-8350. Fax: 
626-395-5939. E-mail: bjorkman@caltech.edu. 
 
Running title: Increased Expression of Dimeric HIV-1 Antibody 2G12 
Word count for abstract: 188  Word count for text: 3710
AC
EPT
ED
 Copyright © 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
J. Virol. doi:10.1128/JVI.01564-08 
JVI Accepts, published online ahead of print on 22 October 2008
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on O
ctober 27, 2008 
jvi.asm.org
D
ow
nloaded from
 
1 
Abstract 1 
The antigen-binding fragment of the broadly neutralizing Human Immunodeficiency 2 
Virus Type 1 (HIV-1) antibody 2G12 has an unusual 3D domain-swapped structure with 3 
two aligned combining sites that facilitates recognition of its carbohydrate epitope on 4 
gp120. When expressed as an intact IgG, 2G12 formed typical IgG monomers containing 5 
two combining sites and a small fraction of a higher molecular weight species, which 6 
showed a significant increase in neutralization potency (50- to 80-fold compared to 2G12 7 
monomer) across a range of clade A and B strains of HIV-1. Here we show that the 8 
higher molecular weight species corresponds to a 2G12 dimer containing four combining 9 
sites, and present a model for how intermolecular 3D domain swapping could create a 10 
2G12 dimer. Based on the structural model for a 3D domain-swapped 2G12 dimer, we 11 
designed and tested a series of 2G12 mutants predicted to increase the ratio of 2G12 12 
dimer to monomer. We report a mutation that effectively increases the 2G12 13 
dimer/monomer ratio without decreasing the expression yield. Increasing the proportion 14 
of 2G12 dimer compared with monomer could lead to a more potent reagent for gene 15 
therapy or passive immunization. 16 
 17 
Introduction 18 
Broadly neutralizing antibodies against Human Immunodeficiency Virus Type 1 (HIV-1) 19 
have attracted attention not only for the lessons they provide for designing vaccine 20 
antigens to induce a more robust immunological response (2), but also as potential 21 
therapeutic reagents. Although HIV infection leads to a vigorous antibody response, most 22 
antibodies fail to control the virus due to targeting of non-neutralizing epitopes or the 23 
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2 
ability of escape mutants to quickly develop against neutralizing antibodies (23). 1 
Correlating with the ability of the virus to elude antibodies, the majority of neutralizing 2 
antibodies are highly strain-specific. Nevertheless, a small set of broadly neutralizing 3 
antibodies has been isolated from the blood of HIV-infected individuals and these 4 
reagents have been extensively studied (2). Clinical trials using a cocktail of three such 5 
antibodies, 2G12, 4E10, and 2F5, have demonstrated a partial ability to suppress viral 6 
replication (13, 20, 21). 7 
The 2G12 antibody has an unusual structure that facilitates recognition of its 8 
carbohydrate epitope on gp120 (4). Whereas typical IgG antibodies contain two flexibly-9 
attached antigen binding fragments (Fabs), resulting in two antigen binding sites 10 
separated by distances ranging from 120 to 150 Å in structures of intact IgGs (6, 7, 17), 11 
the Fab arms of 2G12 are entwined in such a way as to create a single antigen binding 12 
region with two rigidly arranged antigen binding sites separated by ~35 Å (4) (Fig. 13 
1A,B). The entwined structure of the 2G12 Fabs results from 3D domain swapping (1) in 14 
which each 2G12 light chain associates with both heavy chains: the light chain variable 15 
domain (VL) is paired with the variable domain of one heavy chain (VH), while the light 16 
constant domain (CL) is paired with constant domain 1 (CH1) of the partner heavy chain 17 
(Fig. 1B). This domain-swapped arrangement prevents the Fab arms from having the 18 
normal flexibility observed in other antibodies, but by possessing a double-sized antigen-19 
combining site, the 2G12 Fab2 unit is able to recognize clusters of mannose-rich 20 
carbohydrates that occur on gp120 (18). Normally these carbohydrates create a glycan 21 
shield on the HIV envelope glycoprotein (Env) spike that helps the virus evade the host 22 
antibody response (23). 23 
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3 
During expression of 2G12 in mammalian cells, we observed production of IgG 1 
monomers (i.e., two heavy chains, two light chains, and thus two Fabs), as typically 2 
formed by other IgGs, and a higher molecular weight fraction that exhibited a 3 
significantly increased neutralization potency. Here we show that the higher molecular 4 
weight fraction corresponded to a 2G12 dimer with four heavy chains, four light chains, 5 
and four Fabs, and present a model for how 3D domain swapping could create a 2G12 6 
dimer. We used the model of the 2G12 dimer to design mutations predicted to increase 7 
the fraction of dimer being expressed, and report a mutation that effectively increases the 8 
2G12 dimer/monomer ratio without decreasing the expression yield. 9 
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4 
MATERIALS AND METHODS 1 
Materials. Sequences encoding the 2G12 VH-CH1 and VL-CL domains in the pComb3H 2 
expression vector (a gift from Dennis Burton, The Scripps Research Institute) were 3 
subcloned into the bicistronic baculovirus vector pAc-κ-Fc (PROGEN Biotechnik), 4 
which contains the gene for the Fc region of human IgG1 (G1m marker). The heavy 5 
chain gene, now including the hinge and Fc regions (residues 236 to 446, numbered 6 
according to Kabat (11)), and light chain gene were each subcloned into the mammalian 7 
expression vector pTT5 (NRC Biotechnology Research Institute) for expression in 8 
HEK293-6E cells. Mutations were introduced in the 2G12 heavy chain gene using the 9 
QuikChange mutagenesis kit (Stratagene). Seven different forms of the 2G12 heavy chain 10 
gene were constructed: our original 2G12 sequence, which differed from previously-11 
reported 2G12 and IgG1 Fc sequences (4) by two substitutions (V5L and H237S), and six 12 
hinge deletion mutants constructed from our original 2G12 sequence. The mutants were 13 
D1 (deletion of residue 237), D2 (deletion of 236-237), D3 (deletion of 235-237), D4 14 
(deletion of 232-237), D6 (deletion of 232-239), and D6GG (deletion of 232-239 and two 15 
proline to glycine substitutions: P240G and P241G) (Fig. 3A). In addition, we produced 16 
forms of the original 2G12 sequence and of the D2 mutant that reverted the V5L and 17 
H237S substitutions to the previously-reported 2G12 and IgG1 Fc sequences. 18 
 19 
Expression of 2G12. Proteins were expressed using polyethylenimine (PEI)-mediated 20 
transient transfection (5) of suspension HEK 293-6E cells (NRC Biotechnology Research 21 
Institute). The 2G12 heavy and light chain expression vectors were co-transfected at a 1:1 22 
ratio using 25 kDa linear PEI (Polysciences). Cell culture supernatants were collected 6 23 
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5 
days post-transfection, passed over protein A resin (Pierce Biotechnology), and eluted 1 
using pH 3.0 citrate buffer. Eluates from the protein A column were immediately 2 
neutralized and then subjected to size exclusion chromatography in 20 mM Tris pH 8.0, 3 
150 mM NaCl using a Superdex 200 16/60 or 10/30 column (GE Healthcare). The 4 
column profile revealed two major peaks, later identified as 2G12 dimer and 2G12 5 
monomer. Similar results were obtained when the original 2G12 construct and the D2 6 
mutant were purified from cell culture supernatants by passage over a neonatal Fc 7 
receptor (FcRn) affinity column in which supernatants were passed over the column at 8 
pH 6.0 and eluted at pH 8.0 (8). 9 
Since the sizing column profiles of the monomeric and dimeric forms of 2G12 10 
partially overlapped, samples for neutralization assays were subjected to two size 11 
exclusion chromatography purification steps: first the concentrated protein A eluate was 12 
run over a Superdex 200 16/60 column, and then the monomer and dimer fractions were 13 
placed over a Superdex 200 10/30 column. 14 
Parallel trials of the original 2G12 construct and six hinge deletion mutants were 15 
performed on a 400 ml scale. Five independent expression trials, each involving all seven 16 
constructs, were conducted. In each trial, 2G12 proteins were purified on a protein A 17 
column as described above, and then subjected to size exclusion chromatography. Dimer 18 
to monomer ratios for each construct (Fig. 3C) were calculated after integration of the 19 
peak areas using the UNICORN software. In four of the five trials, the expression of total 20 
2G12 protein in each sample was approximately 2 mg/liter. In the fifth trial, the total 21 
expression in each sample was ~10-fold lower, likely due to sub-optimal transfections. 22 
Data from this trial were omitted from the calculated means in Fig. 3C.  23 
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 1 
Static Light Scattering. The oligomeric states of the two 2G12 peaks isolated by 2 
conventional size exclusion chromatography were determined using size exclusion 3 
chromatography with in-line static light scattering and refractive index monitoring. 4 
Experiments were performed at 25 °C using an ÄKTA chromatography system (GE 5 
Healthcare) with a Superdex 200 10/30 (GE Healthcare) equipped with a Dawn Helios 6 
multi-angle light scattering photometer and an Optilab rEX refractive index detector 7 
(Wyatt Technology).  Bovine serum albumin was used as a calibration standard. All data 8 
were analyzed with ASTRA V software (Wyatt Technology). 9 
 10 
In vitro neutralization assays. We used a previously-described pseudovirus 11 
neutralization assay, which measures the reduction in luciferase reporter gene expression 12 
in the presence of a potential inhibitor following a single round of pseudovirus infection 13 
in TZM-bl cells (12, 14). Pseudoviruses were generated by cotransfection of HEK 293T 14 
cells with an Env expression plasmid and a replication-defective backbone plasmid. 15 
Neutralization assays were performed either in-house (data shown only for strain HxBc2) 16 
or by the Collaboration for AIDS Vaccine Discovery (CAVD) core neutralization facility 17 
(Table 1). Strains SC422661.8, TRO.11, PVO.4, QH0692.42, 6535.3, and HxBc2 were 18 
tested in-house, with results similar to those obtained from the CAVD assays. For in-19 
house assays, each 2G12 sample was tested in triplicate, with 200 infectious viral units 20 
per well incubated with a 3-fold dilution series. After a 1 hour incubation at 37 °C, 21 
10,000 TZM-bl cells were added to each well and incubated for 2 days. Cells were then 22 
lysed and assayed for luciferase expression using Bright-Glo (Promega) and a Victor3 23 
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7 
luminometer (Perkin Elmer). Percentage neutralization was determined by calculating the 1 
difference in luminescence between test wells and cell control wells (cell only), dividing 2 
this value by the difference between virus control (cell + virus) and cell control wells, 3 
subtracting from 1 and multiplying by 100. Non-linear regression analysis was used to 4 
calculate concentrations at which half-maximal inhibition was observed (IC50 values). 5 
Average IC50 values reported in Table 1 are geometric means calculated using the 6 
formula (∏ai)(1/n); i = 1, 2, …, n. Calculation of geometric means is suitable for data sets 7 
covering multiple orders of magnitude (19), as is the case for neutralization data across 8 
multiple viral strains. 9 
 10 
Biacore binding studies. A Biacore T100 biosensor system (GE Healthcare) was used to 11 
evaluate binding of the 2G12 proteins to gp120. In this system, a protein is coupled to a 12 
gold-dextran layer and association and dissociation phases for binding to an injected 13 
protein are measured in real time in resonance units (RU). The original 2G12 monomer 14 
and dimer and the D2 dimer (~150 RU of each) were captured onto ~4000 RU of goat 15 
anti-Fc polyclonal antibody (Chromapure, Jackson ImmunoResearch), which was 16 
immobilized by primary amine coupling to a CM5 sensor chip as described in the Biacore 17 
manual. A concentration series of monomeric gp120 (expressed in baculovirus-infected 18 
insect cells; strain HxBc2) was injected at 20 µl/min over the flowcells. After the gp120 19 
dissociation phase, the surface was regenerated by injection of pH 1.5 glycine buffer, and 20 
2G12 proteins were captured again prior to the subsequent gp120 injection. 21 
 22 
ACC
EPT
ED
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on O
ctober 27, 2008 
jvi.asm.org
D
ow
nloaded from
 
8 
Structural analysis. The 2G12 structure was displayed and analyzed using the program 1 
O (10). The 3D model of 2G12 was prepared using SOLIDWORKS (SolidWorks Corp.). 2 
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9 
RESULTS 1 
Identification of a dimeric form of 2G12 with increased neutralization potency. 2 
During purification of 2G12 IgG expressed in mammalian cells, we noticed that the 3 
protein eluted as two peaks from a size exclusion chromatography column (Peak 1, 4 
eluting at ~12 ml and Peak 2, eluting at ~10 ml) (Fig. 2A). Peak 1 migrated as if it was a 5 
somewhat larger protein than a typical IgG, which eluted at ~13 ml, suggesting that it 6 
corresponded to a 2G12 monomer, which has a more elongated structure than other IgG 7 
monomers due to the 3D domain-swapped structure of its Fabs (4) (Fig. 1B). Peak 2 8 
appeared to correspond to a higher molecular weight form of 2G12. Samples from both 9 
peaks migrated on SDS-PAGE under non-reducing conditions as expected for an IgG 10 
(Fig. 2B), indicating that covalent modification(s) could not account for the altered 11 
migration of Peak 2. Once isolated, both peaks retained their size exclusion profile over a 12 
period of weeks to months, indicating that there was little tendency for conversion 13 
between the two forms. 14 
In-line static multi-angle light scattering was used to determine the absolute 15 
molecular masses, and therefore the oligomeric states, of both peaks. For this analysis, 16 
we used the major portion of Peak 2 and did not include the shoulder slightly ahead of the 17 
peak. The experimentally-determined molecular masses derived from these data were 135 18 
kDa for Peak 1 and 285 kDa for Peak 2. By comparing these values with the molecular 19 
mass predicted from the 2G12 sequence (145 kDa), we identified Peak 1 as 2G12 20 
monomer and Peak 2 as 2G12 dimer.  21 
We next compared the potencies of purified 2G12 monomer and dimer to 22 
neutralize a range of HIV-1 pseudoviruses using an in vitro neutralization assay (12, 14). 23 
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10 
The 2G12 monomer neutralized a range of clade A and B, but not clade C, strains (Table 1 
1). Over the range of strains that were sensitive to 2G12 neutralization, the 2G12 dimer 2 
was generally one to two orders of magnitude more potent than the 2G12 monomer, with 3 
an average increased potency of 82-fold (Table 1). Three of the 20 strains that were not 4 
neutralized by monomeric 2G12 (IC50 > 100 µg/ml) were neutralized by dimeric 2G12: 5 
strains TRJO4551.58 (clade B) and strains 211-9 and T280-5 (circulating recombinant 6 
forms) (Table 1). The clade C strains remained resistant to 2G12 dimer (Table 1 legend). 7 
 8 
Design and Expression of 2G12 Mutants. Given that the 2G12 dimer was not formed 9 
by covalent joining of two monomers (Fig. 2B), we reasoned that the dimeric form could 10 
arise from intermolecular 3D domain swapping in which each light chain was paired with 11 
heavy chains derived from two IgGs (Fig. 1C). By contrast, the intramolecular domain 12 
swapping observed in monomeric 2G12 involves the pairing of each light chain with both 13 
heavy chains from a single IgG (4) (Fig. 1B). 14 
To increase the dimeric fraction of 2G12, we designed mutants predicted to favor 15 
intermolecular domain swapping instead of the intramolecular swapping that led to the 16 
monomer. Compared to a typical antibody, the hinge regions of the domain-swapped 17 
2G12 are forced into a relatively extended conformation. In other words, the C-terminal 18 
ends of the 2G12 CH1 domains (defined by residue K228) are held fixed at a large 19 
distance: the K228-K228 distance is 40.6 Å in the 2G12 Fab2 structure (pdb code 1OP3) 20 
(4) versus 25.0 Å for the corresponding distance in an unswapped antibody structure (b12 21 
IgG; pdb code 1HZH) (17). Intramolecular domain swapping, as occurs in monomeric 22 
2G12, may be disfavored by a shorter hinge region, which could instead accommodate an 23 
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11 
intermolecular domain swap resulting in an intertwined IgG dimer instead of an 1 
intertwined IgG monomer (Fig. 1B,C). Based on this structural hypothesis we designed 2 
forms of 2G12 with shorter hinge regions. 3 
A series of deletions was made in the 2G12 heavy chain between residue C230, 4 
which normally participates in a disulfide bond with the light chain, and residues 5 
C239/C242, which form disulfide bonds between the heavy chains (Fig. 3A). The 6 
mutants were named according to how many residues were deleted, with D1 referring to 7 
a single residue deletion, up to D6, which represented a six-residue deletion. An 8 
additional mutant, D6GG, in which two prolines were replaced with glycines to allow 9 
increased flexibility, was also prepared. 10 
The original 2G12 construct was expressed along with the suite of mutants in 11 
multiple expression trials. During each trial, the expressed IgGs were purified from 12 
transfected cell supernatants on a protein A column followed by size exclusion 13 
chromatography to separate 2G12 monomer and dimer. The amounts of dimer and 14 
monomer produced by each construct were determined by integrating the area under the 15 
relevant size exclusion chromatography peak (Fig. 3B). As shown in Fig. 3C, the D2 16 
mutant had a significantly higher dimer/monomer ratio (0.66 ± 0.06) than the original 17 
2G12 (0.28 ± 0.03). The other mutants showed only slightly higher dimer/monomer 18 
ratios (D3-D6, D6GG) or a lower ratio (D1) than the original 2G12. A comparison of the 19 
total expression levels (monomer plus dimer) of the original and D2 constructs showed 20 
that the D2 mutation did not impair overall expression (Fig. 3C). 21 
2G12 protein has been reported to aggregate under strongly acidic conditions 22 
(16). To address whether the low pH used during elution from the protein A column 23 
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12 
affected the ability of 2G12 to dimerize, we purified 2G12 from transfected cell 1 
supernatants using an FcRn affinity column in which samples were loaded at pH 6.0 and 2 
eluted at pH 8.0 (8). Size exclusion chromatography profiles of the original 2G12 and the 3 
D2 mutant were similar for both purification schemes, indicating that dimer formation 4 
was not affected by the protein A elution conditions. In addition, we verified that our 5 
results were not influenced by two substitutions in our 2G12 construct compared to the 6 
published sequences of 2G12 Fab2 and human IgG1 Fc that were introduced during 7 
cloning (Methods). To ascertain the effects of the substitutions, we produced versions of 8 
the original 2G12 construct and the D2 mutant in which the substitutions were reverted, 9 
and found no significant differences in the total yields of 2G12 protein and the 10 
dimer/monomer ratios for the reverted constructs compared to the constructs containing 11 
the two substitutions: the average total yields for both reverted constructs were within 8% 12 
of the unreverted constructs, and the dimer/monomer ratios for the reverted 2G12 and the 13 
D2 mutant constructs were 0.34 ± 0.03 (reverted 2G12) and 0.76 ± 0.06 (reverted D2 14 
mutant).  15 
To verify that the substitutions in the D2 mutant did not affect its neutralization 16 
activity, we determined the neutralization potencies of monomeric and dimeric D2 for the 17 
strains that were tested for the original 2G12 monomer and dimer. As seen for the 18 
original 2G12 dimer, the D2 dimer was more potent in neutralization of 2G12-sensitive 19 
strains than the corresponding monomer, and two of the strains that were resistant to the 20 
original 2G12 monomers were sensitive to D2 2G12 dimers (Table 1). The average IC50 21 
value for the D2 dimer (0.12 µg/ml) was slightly higher than the average value for the 22 
original dimer (0.08 µg/ml), and the overall monomer IC50/dimer IC50 ratio for the D2 23 
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13 
mutant (54-fold) was lower than the corresponding ratio for the original 2G12 dimer (82-1 
fold). However, the differences in neutralization potencies of the D2 and original 2G12 2 
dimers are not necessarily significant because the dimer IC50 averages that were used to 3 
derive the ratios were calculated using strains with IC50 values that were below the 4 
sensitivity limit (0.05 µg/ml) of our assay – these are reported as <0.05 µg/ml in Table 1 5 
and input as 0.05 µg/ml in the calculations of averages. 6 
To address whether dimeric 2G12 exhibits higher neutralization potencies than 7 
monomeric 2G12 because of avidity effects (i.e., higher apparent affinity resulting from 8 
multivalent binding), we compared the binding of gp120 to the two forms of 2G12. In 9 
these experiments, the original 2G12 monomer and dimer and the D2 dimer were coupled 10 
to a biosensor chip, and the binding of injected monomeric HxBc2 gp120 was evaluated. 11 
No significant differences were observed for the interactions with gp120 of the dimers 12 
compared to the monomer – the equilibrium dissociation constants (KDs) were ~ 1 nM for 13 
the binding of gp120 to the original monomer, the original dimer, and the D2 dimer (data 14 
not shown). These results do not rule out avidity effects as a mechanism for increased 15 
neutralization potency, however, since the gp120 monomers would not contain the same 16 
arrangement of carbohydrate epitopes as a trimeric gp120/gp41 envelope spike on the 17 
surface of a virus. 18 
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14 
DISCUSSION 1 
Unlike other known broadly neutralizing anti-HIV-1 antibodies, 2G12 recognizes a 2 
carbohydrate, rather than protein, epitope on gp120 (18, 22). The unusual domain-3 
swapped structure of its Fab2 unit facilitates recognition of adjacent oligomannose units 4 
on the same envelope spike (3). Multimerization of 2G12 has been reported to increase 5 
the neutralization potency of 2G12 – an engineered IgM form of 2G12, which contained 6 
10 Fabs (as compared with 2 in a monomeric IgG) was shown to neutralize up to 28-fold 7 
better than monomeric 2G12 IgG (24). Previous investigators suggested that 2G12 IgG 8 
might form dimers with higher neutralization potency; for example, the several-fold 9 
higher neutralization potency for 2G12 produced in transgenic maize as opposed to 10 
mammalian cells was ascribed to a higher dimer or aggregate content (15), and 2G12 IgG 11 
dimers are mentioned but not characterized or directly compared to 2G12 IgM or 2G12 12 
monomers by Wolbank et al. (24). Here we report a higher molecular weight form of 13 
2G12 IgG that is naturally produced during expression in mammalian cells, and present 14 
biophysical evidence that it represents a dimeric IgG.  15 
We compared the potencies of isolated 2G12 dimer and monomer for 16 
neutralization of a range of clade A and clade B HIV-1 strains, and report that the 2G12 17 
dimer has a >50-fold average increased potency as compared with the monomer. The 18 
high neutralization potency of 2G12 dimers suggests that the dimeric fraction of 2G12 19 
would be a better candidate for passive immunotherapy to treat HIV-1 infection than the 20 
monomeric fraction, which appears to have been used in previous studies of the efficacy 21 
of passive immunization using anti-HIV antibodies (13, 21). Another form of 2G12 that 22 
could be considered for passive immunizations is an engineered IgM form, which was 23 
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15 
reported to exhibit up to a ~28-fold increase in neutralization potency compared to 2G12 1 
IgG (24). Because the previous study used a different neutralization assay and different 2 
viral strains, the average neutralization potency increases cannot be directly compared, 3 
but their similarity in magnitude suggests that the extra Fab2 units in the pentameric IgM 4 
form compared to the dimeric form do not contribute significantly to more effective 5 
neutralization. In any case, the choice of an optimal therapeutic reagent depends on other 6 
factors in addition to neutralization potency, including in vivo half-life, tissue 7 
distribution, antibody dependent cellular cytotoxicity (ADCC) activity, and expression 8 
yield. Given the longer serum half-lives of IgG versus IgM antibodies (9), the activity of 9 
IgG antibodies in ADCC (9), and the more complex assembly and heterogeneity of 10 
recombinant J chain-containing IgM and IgA, the dimeric IgG form of 2G12 is likely to 11 
have several advantages compared with the IgM form. 12 
Based on the propensity of 2G12 monomers to form an intramolecular domain-13 
swapped Fab2 structure, we present a structural model for the organization of the 2G12 14 
dimer that involves intermolecular 3D domain swapping (Fig. 1C). We used the structural 15 
model to design and express 2G12 mutants predicted to have a higher fraction of the 16 
more potent dimeric form. One of these mutants, D2, had a significantly higher dimer 17 
content and equivalent overall expression. Due to the much higher neutralization 18 
potencies of the original and the D2 mutant dimers, a modest fraction of dimer can 19 
dominate the overall potency of a 2G12 preparation with a mixture of forms. Different 20 
2G12 dimer fractions may occur in different expression contexts, perhaps relating to the 21 
density of assembling 2G12 in the endoplasmic reticulum, which could influence the 22 
rates of intra- versus intermolecular domain swapping. Further experiments will be 23 
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16 
required to investigate the extent to which the D2 mutant increases dimer fraction in other 1 
expression systems. Although the mechanism by which the D2 mutant causes a higher 2 
dimer content is not known for certain, this mutant would be a potentially useful 3 
therapeutic reagent in any context in which unfractionated 2G12 is utilized. This includes 4 
gene therapy applications, topical (microbicide) use, and as an injectable reagent.  5 
 6 
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Table 1. IC50 values (µg/ml) for four forms of 2G12 obtained from in vitro pseudovirus 1 
neutralization assays of 2G12-sensitive strains. N.D. = not determined. * = results from 2 
in-house neutralization assays; all other results obtained by the CAVD core neutralization 3 
facility. In calculating average IC50 values, measurements outside of the range of the 4 
assay (<0.05 µg/ml or >100 µg/ml) were assigned to those limiting values, and averages 5 
were calculated using only those strains for which IC50 values were available for all four 6 
forms of 2G12. The following clade B and C strains were not neutralized by the original 7 
2G12 monomer or dimer (IC50  values > 100 µg/ml): AC10.0.29, RHPA4259.7, 8 
THRO4156.18, REJO4541.67, CAAN5342.A2 (clade B) and Du156.12, Du172.17, 9 
Du422.1, ZM197M.PB7, ZM214M.PL15, ZM233M.PB6, ZM249M.PL1, ZM53M.PB12, 10 
ZM109F.PB4, ZM135M.PL10a, CAP45.2.00.G3, CAP210.2.00.E8 (clade C).  11 
 12 
  2G12 original D2 
        
Env clone Clade 
monomer 
IC50 
(µg/ml) 
dimer  
IC50 
(µg/ml) 
monomer IC50/ 
dimer IC50 
monomer 
IC50 
(µg/ml) 
dimer  
IC50 
(µg/ml) 
monomer 
IC50/ 
dimer IC50 
6535.3 B 30.1 0.34 89 32.9 1.5 22 
QH0692.42 B 9.8 0.08 123 11.1 0.1 111 
SC422661.8 B 17.8 <0.05 356 19.4 0.1 194 
PVO.4 B 4.9 <0.05 98 7.1 <0.05 142 
TRO.11 B 1.6 <0.05 32 1.4 <0.05 28 
WITO4160.33 B 6.8 <0.05 136 7.6 0.05 152 
3988.25 B 3.2 <0.05 64 2.8 <0.05 56 
7165.18 B 6.6 <0.05 132 8 <0.05 160 
QH0515.1 B 0.1 <0.05 2 0.1 <0.05 2 
5768.4 B 0.1 <0.05 2 0.1 <0.05 2 
6101.1 B 24 0.05 480 26.5 0.06 442 
TRJO4551.58 B >100 0.16 625 N.D. N.D. N.D. 
*HxBc2 B 0.47 0.028 17 N.D. N.D. N.D. 
        
0330.v4.c3 A 15.3 <0.05 306 17.2 <0.05 344 
3415.v1.c1 A 8 <0.05 160 8.1 <0.05 162 
        
CHO38.12 CRF07_BC 0.2 <0.05 4 0.3 <0.05 6 
211-9 CRF02_AG >100 0.4 250 >100 1.3 77 
235-47 CRF02_AG 1.3 <0.05 26 1.4 <0.05 28 
T280-5 CRF02_AG >100 1 100 51 4.9 10 
T250-4 CRF02_AG 61.5 <0.05 1230 60.7 0.4 152 
T251 CRF02_AG 50.8 0.1 508 46.6 0.3 155 
        
Average 
(geometric 
mean)  6.3 0.08 82 6.5 0.12 54 
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FIGURE LEGENDS 1 
 2 
FIG. 1. Schematic structures of a typical IgG and 2G12. Heavy chains are blue in panels 3 
A and B and blue or red in panel C, light chains are cyan, disulfide bonds are yellow 4 
lines, and the antigen combining sites are yellow starbursts. (A) Schematic diagram 5 
showing the domain arrangement of a typical IgG, which contains two identical heavy 6 
chains and two identical light chains. (B) Schematic diagram (left) and a corresponding 7 
3-dimensional model (right) illustrating chain pairing in monomeric 2G12 (based on 8 
structural data from reference (4)). As a result of intramolecular 3D domain swapping, 9 
each heavy chain forms part of both Fab units to create a rigidly-arranged Fab2 unit. To 10 
distinguish the two heavy chains, they are labeled “1” or “2” in the schematic diagram. 11 
(C) Schematic diagram (left) and corresponding 3-dimenstional model (right) illustrating 12 
chain pairing in dimeric 2G12. The proposed dimer structure resulting from 13 
intermolecular 3D domains swapping has the same domain-swapped Fab2 unit as the 14 
monomer, but the connectivity to the Fc domains is altered. To distinguish the four heavy 15 
chains, they are labeled “1”, “2”, “3”, or “4” in the schematic diagram, and are red in one 16 
of the IgG monomer precursors.  17 
 18 
 19 
FIG. 2. Size exclusion chromatography profile of 2G12. (A) Comparison of the elution 20 
profiles of protein A-purified 2G12 with a typical human IgG. The more elongated 21 
structure of the 2G12 IgG monomer (Peak 1) caused it to elute slightly earlier than 22 
typical IgGs. (B) SDS/ (7.5%) PAGE comparison of a typical human IgG and the 2G12 23 
ACC
EPT
ED
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on O
ctober 27, 2008 
jvi.asm.org
D
ow
nloaded from
 
21 
proteins in Peaks 1 and 2. Samples were run under non-reducing conditions. (C) Multi-1 
angle light scattering data obtained by size exclusion chromatography with in-line light 2 
scattering and refractive index monitoring. UV absorbance at 280 nm is shown in black 3 
and the calculated molecular weight based on multi-angle light scattering data is 4 
indicated in blue with units shown on the right axis. The windows used for calculating 5 
molecular masses of Peak 1 and Peak 2 are shown in grey. 6 
 7 
FIG. 3. 2G12 deletion constructs. (A) Amino acid sequences of the hinge region of the 8 
original 2G12 and the six deletion mutants (left) and approximate location of the hinge 9 
deletions on a schematic structure of a normal IgG (right). (B) Size exclusion 10 
chromatography profiles of the original 2G12 and the deletion mutants. Absorbance 11 
traces are shown for one expression trial, normalized on the monomer peak height. (C) 12 
Dimer/monomer ratios for the original 2G12 and the deletion mutants. Data are presented 13 
as the mean and standard deviation for ratios determined from four independent 14 
expression trials, each of which involved expression of all seven constructs. Also shown 15 
is the mean total expression relative to the original 2G12 construct. The P value 16 
comparing the original 2G12 and the D2 mutant was computed using the two-sided 17 
independent sample t test. 18 
ACC
EPT
ED
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on O
ctober 27, 2008 
jvi.asm.org
D
ow
nloaded from
 
ACC
EPT
ED
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on O
ctober 27, 2008 
jvi.asm.org
D
ow
nloaded from
 
ACC
EPT
ED
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on O
ctober 27, 2008 
jvi.asm.org
D
ow
nloaded from
 
ACC
EPT
ED
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on O
ctober 27, 2008 
jvi.asm.org
D
ow
nloaded from
 
